▎ 摘　　要

NOVELTY - Modifying dendritic cells comprises (a) synthesizing substrates for performing photothermal transfection, (b) coating plasmid containing gene sequence encoding Halotag (RTM: Self-labeling protein tag) protein with polyetherimine, and then placing plasmid on the surface of substrate, (c) preparing modified dendritic cells, (d) synthesizing functional glycopolymer molecules, and (e) mixing the functional glycopolymer molecules and modified dendritic cells, and incubating to obtain dendritic cells modified with functional glycopolymer molecules. USE - The modified dendritic cell is useful in preparing medicine for treating and preventing malignant tumors (at least one of lung cancer, liver cancer, colon cancer (preferred), melanoma, prostate cancer, gastric cancer, breast cancer, chronic lymphocytic leukemia and chronic myeloid leukemia) (claimed). ADVANTAGE - The method: is based on cell membrane surface modification technology; can greatly modify glycopolymer with specific recognition to the surface of dendritic cells; can improve the interaction between dendritic and T cells; can improve the activation efficiency of T cells and efficiency of cell transfection; and improves the activity of cells after transfection and overall safety of transfection system. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) dendritic cell prepared by the above method; and (2) vaccine composition comprising dendritic cell, at least one of vectors, adjuvants and excipients.